[To learn English]
Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in a late-stage study, data showed, bolstering its case for benefits beyond weight loss as competition in obesity drugs intensifies.
The drug, survodutide, was licensed from Denmark's Zealand Pharma. An injectable that mimics the proteins GLP-1 and glucagon to create a feeling of fullness, its weight-loss trial results were announced in April, showing patients lost an average of 16.6% over 76 weeks.
勃林格殷格翰周日表示，其实验性减肥药在一项后期研究中显示能减少内脏脂肪和肝脏脂肪，同时最大限度减少肌肉流失，增强了该药物在激烈竞争中不仅看减重数字的论据。
该药物名为 survodutide，从丹麦 Zealand Pharma 获得许可。这是一种注射剂，通过模拟 GLP-1 和 glucagon 蛋白产生饱腹感，其减重试验结果已于 4 月公布，显示患者在 76 周内平均减重 16.6%。
LearnEnglish Leave a remark